Compounds > vatalanib
Page last updated: 2024-09-04

vatalanib and cyc 202

vatalanib has been researched along with cyc 202 in 5 studies

Compound Research Comparison

Studies
(vatalanib)		Trials
(vatalanib)		Recent Studies (post-2010)
(vatalanib)		Studies
(cyc 202)		Trials
(cyc 202)		Recent Studies (post-2010) (cyc 202)
27642989797393

Protein Interaction Comparison

ProteinTaxonomyvatalanib (IC50)cyc 202 (IC50)
Chain A, Homo sapiens cyclin-dependent kinase 2Homo sapiens (human)0.4
Chain C, Cell division protein kinase 2Homo sapiens (human)0.21
Chain C, Cell division protein kinase 2Homo sapiens (human)0.21
Dual specificity protein kinase CLK2Mus musculus (house mouse)0.71
Dual specificity protein kinase CLK4Mus musculus (house mouse)0.62
Cyclin-T1Homo sapiens (human)0.7646
G2/mitotic-specific cyclin-B2Homo sapiens (human)0.55
Serine/threonine-protein kinase PAK 4Homo sapiens (human)6.9
G1/S-specific cyclin-E2Homo sapiens (human)0.498
cGMP-dependent protein kinase 1 Bos taurus (cattle)0.305
cAMP-dependent protein kinase catalytic subunit alphaBos taurus (cattle)0.305
Vitamin K-dependent protein CHomo sapiens (human)2.69
Cyclin-dependent kinase 1Homo sapiens (human)1.0801
G2/mitotic-specific cyclin-B1Homo sapiens (human)1.2287
G2/mitotic-specific cyclin-BMarthasterias glacialis (spiny starfish)0.37
Synapsin-1Bos taurus (cattle)1
Glycogen synthase kinase-3 betaRattus norvegicus (Norway rat)0.305
Cyclin-A2Homo sapiens (human)0.8752
Dual specificity protein kinase CLK1Mus musculus (house mouse)2.75
G1/S-specific cyclin-E1Homo sapiens (human)0.2638
Cyclin-dependent kinase 2Homo sapiens (human)0.4921
Mitogen-activated protein kinase 1Homo sapiens (human)0.3167
Casein kinase I isoform alphaHomo sapiens (human)4
Casein kinase I isoform deltaHomo sapiens (human)10
Cyclin-dependent kinase 7Homo sapiens (human)0.5635
Cyclin-dependent kinase 9Homo sapiens (human)0.7534
Cyclin-HHomo sapiens (human)0.5614
CDK-activating kinase assembly factor MAT1Homo sapiens (human)2.2
Cyclin-A1Homo sapiens (human)1.3611
Casein kinase I isoform alphaRattus norvegicus (Norway rat)0.312
Cyclin-dependent-like kinase 5 Homo sapiens (human)0.3492
Cyclin-dependent-like kinase 5Bos taurus (cattle)0.2
Squalene synthaseRattus norvegicus (Norway rat)0.17
Dual specificity tyrosine-phosphorylation-regulated kinase 1AHomo sapiens (human)2.0437
Cyclin-dependent kinase 5 activator 1Homo sapiens (human)0.3764
Dual specificity tyrosine-phosphorylation-regulated kinase 1AMus musculus (house mouse)5
G2/mitotic-specific cyclin-B3Homo sapiens (human)0.55
Dual specificity tyrosine-phosphorylation-regulated kinase 2Homo sapiens (human)1.7
Cyclin-dependent kinase 1Oryzias latipes (Japanese medaka)0.37
Dual specificity tyrosine-phosphorylation-regulated kinase 1BHomo sapiens (human)1.2

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (60.00)29.6817
2010's2 (40.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Atteridge, CE; Azimioara, MD; Benedetti, MG; Biggs, WH; Carter, TA; Ciceri, P; Edeen, PT; Fabian, MA; Floyd, M; Ford, JM; Galvin, M; Gerlach, JL; Grotzfeld, RM; Herrgard, S; Insko, DE; Insko, MA; Lai, AG; Lélias, JM; Lockhart, DJ; Mehta, SA; Milanov, ZV; Patel, HK; Treiber, DK; Velasco, AM; Wodicka, LM; Zarrinkar, PP1
Bullock, AN; Fedorov, O; Knapp, S; Marsden, B; Müller, S; Pogacic, V; Rellos, P; Schwaller, J; Sundström, M1
Atteridge, CE; Campbell, BT; Chan, KW; Ciceri, P; Davis, MI; Edeen, PT; Faraoni, R; Floyd, M; Gallant, P; Herrgard, S; Hunt, JP; Karaman, MW; Lockhart, DJ; Milanov, ZV; Morrison, MJ; Pallares, G; Patel, HK; Pritchard, S; Treiber, DK; Wodicka, LM; Zarrinkar, PP1
Russu, WA; Shallal, HM1
Aiche, S; Bassermann, F; Becker, W; Canevari, G; Casale, E; Depaolini, SR; Ehrlich, HC; Felder, ER; Feuchtinger, A; Garz, AK; Gohlke, BO; Götze, K; Greif, PA; Hahne, H; Heinzlmeir, S; Helm, D; Huenges, J; Jeremias, I; Kayser, G; Klaeger, S; Koch, H; Koenig, PA; Kramer, K; Kuster, B; Médard, G; Meng, C; Petzoldt, S; Polzer, H; Preissner, R; Qiao, H; Reinecke, M; Reiter, K; Rueckert, L; Ruland, J; Ruprecht, B; Schlegl, J; Schmidt, T; Schneider, S; Schoof, M; Spiekermann, K; Tõnisson, N; Vick, B; Vooder, T; Walch, A; Wilhelm, M; Wu, Z; Zecha, J; Zolg, DP1

Other Studies

5 other study(ies) available for vatalanib and cyc 202

ArticleYear
A small molecule-kinase interaction map for clinical kinase inhibitors.
    Nature biotechnology, 2005, Volume: 23, Issue:3

    Topics: Benzamides; Drug Design; Escherichia coli; Escherichia coli Proteins; Imatinib Mesylate; Microchemistry; Pharmaceutical Preparations; Piperazines; Protein Binding; Protein Interaction Mapping; Protein Kinase Inhibitors; Pyrimidines

2005
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
    Proceedings of the National Academy of Sciences of the United States of America, 2007, Dec-18, Volume: 104, Issue:51

    Topics: Amino Acid Sequence; Binding Sites; Clinical Trials as Topic; Drug Evaluation, Preclinical; Enzyme Stability; Humans; Molecular Sequence Data; Phylogeny; Protein Array Analysis; Protein Conformation; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases

2007
A quantitative analysis of kinase inhibitor selectivity.
    Nature biotechnology, 2008, Volume: 26, Issue:1

    Topics: Binding Sites; Enzyme Activation; Humans; Phosphotransferases; Protein Binding; Protein Interaction Mapping; Protein Kinase Inhibitors; Proteome; Quantitative Structure-Activity Relationship

2008
Discovery, synthesis, and investigation of the antitumor activity of novel piperazinylpyrimidine derivatives.
    European journal of medicinal chemistry, 2011, Volume: 46, Issue:6

    Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Discovery; Drug Screening Assays, Antitumor; Humans; Models, Molecular; Molecular Structure; Piperazines; Protein Kinase Inhibitors; Protein Kinases; Pyrimidines; Stereoisomerism; Structure-Activity Relationship

2011
The target landscape of clinical kinase drugs.
    Science (New York, N.Y.), 2017, 12-01, Volume: 358, Issue:6367

    Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cytokines; Drug Discovery; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Mice; Molecular Targeted Therapy; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proteomics; Xenograft Model Antitumor Assays

2017